Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Novartis AG stands third among the most undervalued ...

The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

Novartis’ open-label, multi-centre, 1:1 randomised phase 3 PSMAfore trial with Pluvicto – a prostate-specific membrane antigen – evaluated 469 participants and met the primary endpoint of ...

Novartis has high hopes for newly launched heart drug Leqvio and cancer therapy Pluvicto. To hear CEO Vas Narasimhan tell it, both products are off to a strong start in their multiyear journeys to ...

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the second quarter of 2025 and upped annual ...

Sales of Kisqali, which treats metastatic breast cancer, surged 64% globally on a constant currency basis in the three months to June, the company said in its second-quarter sales report. That ...

EAST HANOVER, N.J., March 23, 2022 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) (formerly ...

The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in ...

Novartis has been steadily investing in radiopharmaceuticals over the last few years, and one of those deals has just paid off with an FDA approval for Pluvicto, the first targeted radioligand ...